You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Litigation Details for Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2007)

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-11-29
Court District Court, D. Delaware Date Terminated 2011-12-20
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Patents 4,551,456; 4,980,470; 5,880,283
Attorneys David B. Abramowitz; Francis J. Murphy , Jr.; Keith D. Parr; Kevin M. Nelson; Maryellen Noreika; Scott B. Feder
Link to Docket External link to docket
Small Molecule Drugs cited in Senju Pharmaceutical Co. Ltd. v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-11-29 1 Complaint 4,780,465 10/1988 Ogata et al. ............. 514/254 4,980,470 12/1990 Masuzawa etal. ...... 544/363 5,043,450…expiration of either the ‘045 patent or U.S. Patent 5,880,283 (the ‘283 patent). 26. Apotex Corp. in its…ingcmcnt of United States Letters Patent No. 6,333,045 (‘045 Patent) under 35 U.S.C. §271(€) (2). THE…interest in the ‘045 patent. 19. Allergan is the exclusive licensee of the ‘045 patent for ophthahnic uses…expiration of a listed patent to provide notice to the owner of the listed patent(s) and to the NDA holder External link to document
2010-11-03 129 in view of U.S. Patent Nos. 4,980,470 ("the '470 patent") and 4,551,456 ("the '… the validity of claim 7 of U.S. Patent No. 6,333,045 (the 045 patent). Order Setting Teleconference:(…validity of claim 7 of U.S. Patent No. 6,333,045 (lithe '045 patent"). 1. Background…#39;456 patent"), rendered claim 7 of the '045 patent obvious. (Id. at 37~38) …ophthalmic compositions. ('456 patent at col. 2:5-10) The '470 patent, which discloses the compound External link to document
2011-12-20 150 at 109) 10. U.S. Patent No. 4,551,456 ("the '456 patent"), teaches that quinolones…alia, the '045 patent and U.S. Patent No. 4,980,470 ("the '470 patent") 2 in connection…view of the '456 patent and the '470 patent, renders the '045 patent obvious; i.e., …quot;) are co-owners of U.S. Patent No. 6,333,045 ("the '045 patent"). (D.I. 100, ex. 1 at…with the '470 patent ended on June 15, 2010, after which time only the '045 patent remains to forestall External link to document
2008-06-23 32 Stipulation of Dismissal above-styled action that United States Patent No. 5,880,283 (the ‘“283 patent”) Wonld not be infringed by Apotex…]l infringe United States Patent No. 6,333,045 (hereinafter the “‘045 patent”) under 35 U.S.C. § 271(e…Apotex Inclia infringes or Will infringe the ‘045 patent under 35 U.S.C. § 271(b) and (c) (Count III of …Count III of the Counterc]airns) and that the ‘283 patent is invalid (Count IV of the Counterclaims); Case… PVT. Ltd. or others, unless and until the ‘283 Patent has expired, been abandoned or withdrawn, or been External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.